Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Total Liabilities (2017 - 2025)

KalVista Pharmaceuticals' Total Liabilities history spans 11 years, with the latest figure at $155.4 million for Q2 2025.

  • On a quarterly basis, Total Liabilities rose 439.1% to $155.4 million in Q2 2025 year-over-year; TTM through Apr 2025 was $155.4 million, a 439.1% increase, with the full-year FY2025 number at $155.4 million, up 439.1% from a year prior.
  • Total Liabilities hit $155.4 million in Q2 2025 for KalVista Pharmaceuticals, up from $130.5 million in the prior quarter.
  • Over the last five years, Total Liabilities for KALV hit a ceiling of $155.4 million in Q2 2025 and a floor of $7.6 million in Q1 2021.
  • Historically, Total Liabilities has averaged $44.0 million across 4 years, with a median of $25.4 million in 2024.
  • Biggest five-year swings in Total Liabilities: plummeted 42.06% in 2021 and later soared 439.1% in 2025.
  • Tracing KALV's Total Liabilities over 4 years: stood at $14.8 million in 2021, then skyrocketed by 63.95% to $24.3 million in 2023, then surged by 436.93% to $130.5 million in 2024, then grew by 19.1% to $155.4 million in 2025.
  • Business Quant data shows Total Liabilities for KALV at $155.4 million in Q2 2025, $130.5 million in Q4 2024, and $26.8 million in Q4 2024.